[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"trastuzumab-emtansine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:trastuzumab-emtansine":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100587471","trastuzumab-emtansinet-dm1-after-trastuzumab-deruxtecant-dxd-in-her2-positive-breast-cancer-in-korea-100587471",false,"NCT06928818","Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea","Prospective Observational Study of Trastuzumab Emtansine Immediately After Trastuzumab Deruxtecan in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Korea","Inclusion Criteria:\n\n* HER2-positive, advanced (unresectable locally advanced or metastatic) breast cancer\n* Prior treatment with trastuzumab deruxtecan(T-DXd) in the advanced setting\n* Intention to treat with Trastuzumab Emtansine (T-DM1) as first therapy upon T-DXd progression\n\nExclusion Criteria:\n\n* Any systemic treatment, other than T-DM1, for breast cancer after trastuzumab deruxtecan (As an exception, patients treated with endocrine agents, not in combination with cytotoxics or antibody-drug conjugates, will be permitted in the study)\n* Has been previously treated with T-DM1 for advanced breast cancer\n* Has been previously treated with 4 or more lines of therapy for advanced breast cancer\n\n  * Half (50%) or more patients will be those who were treated with second-line trastuzumab deruxtecan (i.e. patients at the later line will be capped).","ALL","19 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","Prospective observational study of trastuzumab emtansine immediately after trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer in Korea",[24,25,26],"Cancer of Breast","Trastuzumab Emtansine","Trastuzumab Deruxtecan","RECRUITING","2026-04-21",{"date":30,"type":31},"2026-04-23","ACTUAL",{"date":33,"type":31},"2025-02-26",{"date":35,"type":20},"2029-09-30",{"name":37,"class":38},"Seoul National University Hospital","OTHER"]